Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$47.64 USD
+17.46 (57.85%)
Updated Sep 9, 2025 04:00 PM ET
After-Market: $47.63 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Tourmaline Bio, Inc. has a market cap of $775.39M, which represents its share price of $30.18 multiplied by its outstanding shares number of 25.69M. As a small-cap company, TRML's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TRML 47.64 +17.46(57.85%)
Will TRML be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRML
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital